RespireRx Pharmaceuticals Inc (fka RSPI)

[LTListener]

I read another article by the RSPI science team discussing their KRM-ll-81 compared to other gabakines in development. Specifically compared to similar darigabat from Cerevel. Darigabat appears to have been acquired by Abbvie and is in development for epilepsy. However, in the publication by RSPI team, it appears by their preclinical numbers that KRM-ll-81 is possibly far superior.

It looks like Abbvie acquired Cereval and lists darigabat in PR as one of several important pipeline assets, but it was important enough to make it into PR...

So considering both the AMPA program potential and also the GABA program with NIH preclinical success and comparatively to other gabakines.. How much are these assets really worth NOW? The more due diligence and comparisons to other pharma's similar pipelines, one has to really wonder why this is not sitting at a 100 million valuation AND on the cusp of multiple phase 1 and 2 trials that can make this a billion dollar pipeline!

Yet this emabarrassingly sits on the EM.... what purpose does this serve the stakeholders and executing on the potential in this valuable pipeline???